Skip to main content

Palliative Care

Drug–Drug Interactions Linked to Inferior Survival in Older Patients with Aggressive Lymphoma
Palliative Care
TOP - February 2017, Vol 10, No 1
Although the prevalence of high-grade, aggressive non-Hodgkin lymphoma increases with age, survival outcomes for older patients are disproportionately inferior to those for younger patients. Read More ›
Drug–Drug Interactions Linked to Inferior Survival in Older Patients with Aggressive Lymphoma
By Chase Doyle
Palliative Care
TOP - February 2017, Vol 10, No 1
Although the prevalence of high-grade, aggressive non-Hodgkin lymphoma increases with age, survival outcomes for older patients are disproportionately inferior to those for younger patients. Read More ›
Delirium Symptoms More Severe in Patients Treated with Antipsychotics
Delirium Symptoms More Severe in Patients Treated with Antipsychotics
By Meg Barbor, MPH
Palliative Care
TOP - February 2017, Vol 10, No 1
Adult hospice and palliative care patients with hyperactive delirium symptoms who were given risperidone or haloperidol had greater delirium symptoms at 72 hours than those given placebo. Read More ›
Nurses May Help Drive Integration of Palliative Care for Radiation Therapy Patients
By John Schieszer
Palliative Care
Web Exclusives

Due to the tremendous physical, psychological, and economic burdens of end-stage diseases, there now is an increasing need for palliative care as an integral part of the treatment plan in the management of radiation oncology patients, according to Marilyn Haas, PhD, nurse practitioner at CarePartners Supportive and Palliative Services, Asheville, North Carolina. In addition, she said that integrating palliative care earlier rather than later may be especially important in those patients with metastatic disease.

Read More ›

Flaxseed No More Effective Than Placebo for Hot Flashes
Supportive Care, Conference Correspondent, Palliative Care
August 2011 Vol 4, No 5

CHICAGO—Flaxseed failed to have a significant effect on reducing hot flashes in women compared with placebo, according to results of a randomized, placebo-controlled trial supported by the North Central Cancer Treatment Group. The study included breast cancer survivors as well as women who had never had breast cancer who experienced frequent hot flashes throughout the day and night.

Read More ›
Novel Dosing of Rasburicase Reduces Cost of Prevention
Supportive Care, Palliative Care
August 2011 Vol 4, No 5

ORLANDO—Novel dosing regimens of rasburicase can prevent tumor lysis syndrome (TLS) at costs that are much lower than conventional dosing, according to studies presented at the 2010 American Society of Hematology Annual Meeting & Exposition.

Read More ›